Market research reports on: Pharmaceutical manufacture, cancer, oncology, prevention and treatment, therapeutics, vaccines, clinical studies, drug delivery, immunology, immunotherapy and others.Get a Quote
205 Reports in Pharmaceuticals
The global rare disease diagnostics market should reach $26.7 billion by 2024 from $17 billion in 2019 at a compound annual growth rate (CAGR) of 9.5% for the forecast period of 2019 to 2024.
The global market for pain management patches should grow from $4.2 billion in 2018 to $5.3 billion by 2023, at a compound annual growth rate (CAGR) of 4.5% for the period of 2018-2023.
This report focuses on epidemiology, research and development, current treatment and diagnostics and global response to selected pandemics of the past decade (2009-2020). The report discusses lessons learned from previous outbreaks in terms of policies and measures of prevention and control.
The global market for antifungal drugs should grow from $14.6 billion in 2019 to reach $17.6 billion by 2024, at a compound annual growth rate (CAGR) of 3.8% for the forecast period of 2019-2024.
The goal of this study is to provide information on the global health technology approval process in North America, Europe and the Asia-Pacific region. The study emphasizes the role of HTA and its function and technology process in the pharmaceutical industry. The report also elaborates on recent HTA approvals and their significance on pricing and reimbursement.
According to the National Science Foundation (NSF) the term nano refers to particles, structures, or devices having at least one dimension below 100 nm. Development, manufacturing and sale of these products have spawned a multibillion industry, commonly referred to as the nanotechnology sector. This report gives a market outlook of nanotechnology in cancer treatment and provides information on its most relevant applications. The major trends, issues and recent achievements in nanotechnology-based cancer treatment are also discussed.
The hyperkalemia market is currently a flourishing market, with a strong drug pipeline and upcoming technologies for the diagnosis of conditions. This report on Hyperkalemia Market highlights market dynamics such as drivers, restraints, opportunities and trends that impact the growth of the market. BCC Research focuses on the comprehensive analysis of the current market for hyperkalemia and the future direction of the market.
This report on Medical Affairs highlights overall growth due to rapidly changing pharmaceutical and medical device markets by forming new paradigms and employing marketing strategies that increase market share. The research will provide information on leading market competitors, their market share, partnerships, collaborations, mergers and acquisitions between pharmaceutical companies. BCC Research focuses on the importance of medical affairs in communicating and collecting the medical evidence with the organization and external stakeholders.
The goal of this short study is to help companies operating within the life science sector gain valuable insights on bioinks by providing an overview of types, compositions, and applications of bioinks. This report outlines the trends that are expected to contribute to market growth for these materials.
This comprehensive report provides an in-depth assessment of the global market for non-injectable insulin. The report's key objective is to analyze areas of opportunities, key developments and the impact of this technology on industry, specifically the pharmaceutical, biotechnology and healthcare sectors. The analysis also reviews the adoption of non-injectable insulin in developed and emerging markets.
In the context of the huge impact of generic drug development and its implication in cost savings, an attempt has been made to analyze various pharmaceutical original products which experience patent expiry and likely to go off patents. The report also covers a section illustrating the case for development and opportunities that lie for manufacturers engaged in the generic or biosimilar business for the key drugs.
This report is designed to investigate recent years of performance of pharmaceutical and biopharmaceutical companies with respect to return on investment (ROI) in research and development (R&D), and to discuss ways that companies are trying to improve ROI through 2024. Investigation will include Country/Regional market trends with top areas of return, 2014-2024. This report also looks at which companies are already using artificial intelligence (AI) and machine learning (ML) to successfully compete globally.
The global pediatric market should grow from $92.6 billion in 2019 to reach $116.6 billion by 2024 at a compound annual growth rate (CAGR) of 4.7% for the period of 2019-2024.
The global cannabis market should grow from $25.6 billion in 2019 to $77.6 billion by 2024 at a compound annual growth rate (CAGR) of 24.8% for the period of 2019-2024.
This report on Over-the-Counter (OTC) drugs and dietary supplement products market highlights primary healthcare and its various parameters such as the drafting of rules and regulations for OTC drugs and dietary supplements, the number of drugs classified, self-care awareness among consumers and the size of distribution networks, OTC drugs and dietary supplements manufacturers. BCC Research analyzed key categories and regions to determine the present and future OTC drugs and dietary supplement products market status and forecasted market growth.
This report provides information on significant drug launches in 2019. The study provides an overview of each drug, scientific summaries, pharmacodynamics, pharmacokinetics and clinical trial information, disease backgrounds, analysis of the market, competitors and company profiles of manufacturers. The objective of this study is to present a comprehensive analysis of the current market and its future direction.
The global market for communicable disease should grow from $57.7 billion in 2019 to $69.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.8% for the period of 2019-2024.
This report presents a perspective on the adoption of continuous manufacturing technologies by pharmaceuticals, the role of the FDA and implications for the generics sector.
The global market for neurology should grow from $33.3 billion in 2019 to $39.4 billion by 2024 at a compound annual growth rate (CAGR) of 3.5% for the period of 2019-2024.
The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce off target effect.This report will assess the latest developments in the IL-2 research and development and explore the novel strategies companies are adopting to augment immune response and avoid off target effects in a wide range of conditions including, metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse remitting multiple sclerosis (RRMS), Type 1 diabetes (T1D), as a prophylaxis post-transplant and allergic conditions.What's coming: There are more than 200 studies underway evaluating IL-2 based therapies either as a monotherapy or in combination. The key products and companies that we believe are worth watching in this space are summarized.
The “Market at a Glance Pharmaceuticals” provides an access to all the market share analysis segments of the best-selling and key pharmaceutical reports of BCC Research. This report is a destination for the competitive landscape in the markets that hold a significant stand in the pharmaceuticals sector. Company profiles for all the notable manufacturers in the global pharmaceutical industry are provided as a part of this report.
Posttranslational modifications hit prime time in the pharma industry. There probably isn’t a medium sized biopharmaceutical that does not have an active program ongoing, and certainly all of the big pharma companies are running multiple programs, and collaborations, for what we might have previously termed “undruggable targets”. Many of these are for highly unmet needs in neurodegeneration. The properties of the structure that forms between a target, a degrader and an E3 ligase, are under intense investigation. Minor changes affect how the drugs work - this can explain how promiscuous target-binding payloads can achieve super selectivity when transformed into a degrader. These minor alterations can also render the molecule complex not only ineffective, but sometimes toxic. However, clinical results are beginning to write a compellingly effective story – the long and winding history of research into the ubiquitin proteasome may well have more blockbusters in store for us. And cures in a once overlooked corner of the cell machinery architecture.
The global colorectal cancer therapeutics market should reach $18.5 billion by 2023 from $13.7 billion in 2018 at a compound annual growth rate (CAGR) of 6.1% for the period 2018 to 2023.
The global market for drugs of abuse (DOA) testing should grow from $3.5 billion in 2018 to $4.6 billion by 2023 with a compound annual growth rate (CAGR) of 5.6% for the period of 2018-2023.
The global market for laboratory animal models should grow from $5.9 billion in 2018 to $7.8 billion by 2023, increasing at a compound annual growth rate (CAGR) of 5.6% for the period of 2018-2023.
3 Upcoming Reports in Pharmaceuticals
An overview of the global markets for pharmaceuticals, specifically healthcare legislation and regulation, pricing mechanisms, and reimbursement procedures.
Get a detailed overview of the global markets for pharmaceuticals for women's health and coverage of different events like mergers and acquisitions, agreements, collaborations, and partnerships within the industry.
Get an overview of the global outsourcing market for drug and medical device development and discussion on their services and technologies.